New AAN guidelines on botulinum toxin for spasticity, migraine and other disorders released

Written by Alice Weatherston

In a presentation that took place yesterday at the American Academy of Neurology (AAN) 68th Annual Meeting (15 – 21st April, Vancouver, BC, Canada) new AAN guidelines for the use of botulinum toxin for spasticity, cervical dystonia, blepharospasm and migraine were released based on recent updates in research. Currently four noninterchangeable preparations of botulinum toxin are available in the USA – the new guideline assessed each of these formulations separately for each of the identified conditions. A research team reviewed all available literature on the use of botulinum toxin in the disorders, concluding that the drug is generally safe and...

To view this content, please register now for access

It's completely free